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LETTERS TO THE EDITOR
Vitamin D Receptor Polymorphism and Calcipotriol Response
in Patients with Psoriasis
To the Editor:
Calcitriol, the physiologically active form of vitamin D, has been
shown to induce an anti-proliferative response and differentiation in
basal keratinocytes in vitro. These properties have led to the development
of the noncalcaemic analog, calcipotriol, which has been used success-
fully in the treatment of psoriasis. Most of the pleiotropic actions of
calcitriol are mediated by interaction with the vitamin D receptor
(VDR), a member of the nuclear hormone receptor superfamily and
a ligand-inducible transcription factor. Subsequent homodimerization
or heterodimerization with a retinoic acid receptor-ligand complex
precedes binding to the promoters of vitamin D-inducible
genes. Several mutations in both the ligand and the DNA binding
domains of the VDR gene have been demonstrated to be causative in
patients with calcitriol-resistant rickets (Kristjansson et al, 1993).
Experiments examining the anti-proliferative effects of calcitriol
demonstrated that µ25% of psoriatic patients possessed dermal
fibroblasts that exhibited partial resistance to calcitriol (Smith et al,
1988). In addition, recent studies involving assessment of VDR mRNA
in psoriatic lesional biopsies taken from calcitriol and vehicle treated
plaques reported that it was upregulated µ2.4-fold in calcitriol-treated
plaques, relative to vehicle treatment in responders. Conversely, no
upregulation of VDR mRNA was observed in calcitriol-treated plaques
from patients who displayed no significant improvement, suggesting
that response to vitamin D therapy in psoriasis is determined by the
ability to upregulate transcription or stability of this gene (Chen et al,
1996). We therefore hypothesized that alleles of polymorphic regions
within the VDR gene may contribute to the observed phenomenon
of nonresponsiveness to calcipotriol therapy in µ25% of psoriatic
patients. A single base transition in the human VDR gene characterized
as a T for C change in intron 8, eliminating a BsmI restriction site,
has been strongly associated with low bone mineral density in certain
populations (Morrison et al, 1994). Although it was initially suggested
that this polymorphism may account for up to 75% of the total genetic
effect on bone density, the association has been unreproducible in
several other populations (Hustmyer et al, 1994; Looney et al, 1995).
We have analyzed this polymorphism in a local population of 92
patients with chronic plaque psoriasis using genomic polymerase
chain reaction, restriction digestion, and agarose electrophoresis-based
methodologies, and classified patients into calcipotriol responder groups,
based on consistent evaluation of clinical parameters. The patients were
managed and assessed by one dermatologist. They were prescribed
calcipotriol ointment and asked to apply sufficient to produce a white
layer over the plaques, up to a limit of 100 g per week, for a minimum
of 4 mo. At 6-weekly follow-up visits, the compliance with therapy
and response was assessed. The clinical response was graded on a linear
analog scale, from 0 (no response) to 10 (complete clearance). Patients
were then grouped into one of three clinical response categories,
defined as minimal (0–3), intermediate (4–7), and excellent (8–10).
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We found no correlation between VDR genotype and clinical
responsiveness to calcipotriol in our population (Table I). No statistic-
ally significant differences were observed between any of the three
groups and the frequency or carriage of either allele. In addition,
we found no association between the polymorphism and psoriasis
susceptibility in a larger psoriatic population of 175 individuals, either
as a disease group overall or as subgroups, when divided into early and
late-onset disease and compared with an ethnically matched, local
control population of 124 individuals [allelic frequencies: b 5 0.54,
B 5 0.46 (controls); b 5 0.58, B 5 0.42 (total psoriasis)]. Similarly, no
correlation was observed between VDR alleles and severity of psoriasis,
as assessed by division of patients into those undergoing systemic
therapy and those using topical therapy alone.
These findings contrast with recently published data, reporting a
strong association between responsiveness to topical and oral calcitriol
therapy and the VDR BsmI genotype in a psoriatic population of 48
individuals, in which 11 of 13 patients who exhibited a significant
improvement following therapy carried the bb genotype, compared
with none of 15 patients who demonstrated resistance to the treatment
(Holick et al, 1996). These data indicate an association of the more
common (b) allele with responsiveness to vitamin D treatment, and
calcitriol therapeutic resistance has been reported to be associated
with a failure to upregulate transcription of VDR mRNA following
treatment; however, minigene reporter construct data suggested that
the b allele is actually associated with lower transcription levels of the
VDR gene (Morrison et al, 1994).
The discrepancy between the two studies may be explained by the
differences in the sizes of population used, the use of calcitriol in the
previous study, utilization of more sensitive genotyping methods in
this study (polymerase chain reaction-based screening protocols, as
opposed to Southern blot detection), and differences in the clinical
assessment of response to vitamin D analogs. This study also confirms
recent findings in a smaller Finnish population (Kontula et al, 1997)
and excludes ethnicity of psoriatic populations as a possible factor
influencing the present results. Further linkage studies utilizing proximal
polymorphic markers and analysis of VDR mRNA sequences from
psoriatic patients would be required to definitively exclude this gene
as a candidate in the treatment of psoriatic lesions; however, the current
data fail to support the hypothesis that alleles of the VDR gene
contribute to either the resistance to calcipotriol therapy observed in
µ25% of patients, or the genetic susceptibility to psoriasis.
Table I. BsmI polymorphism in the VDR gene does not
correlate with response to calcipotriol treatment in 92 patients
with chronic plaque psoriasis
Genotypea Frequencyb Carriagec
Calcipotriol response n bb bB BB b B b B
Minimal 19 8 5 6 0.55 0.45 0.68 0.58
Intermediate 45 17 19 9 0.59 0.41 0.80 0.62
Excellent 28 11 11 6 0.59 0.41 0.79 0.61
aNumber of individuals.
bAllelic frequencies within the responder groups.
cCarriage rates of each allele within responder groups.
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densa of human epidermal basement membrane. BPAG2 remains the
first molecule shown to extend from the cytoplasm of basal keratinocytes
to the lamina densa of epidermal basement membrane.
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